

# THE AMERICAN JOURNAL OF MANAGED CARE®

## Publishing Staff

Senior Vice President  
of Clinical Affairs  
**Jeff D. Prescott, PharmD, RPh**

Clinical Projects Managers  
**Kara Guarini, MS**  
**Ida Delmendo**

Senior Project Manager  
**Christina Doong**

Quality Assurance Editor  
**David Allikas**

Assistant Editor  
**Jeanne Linke**

Vice President, Group Creative Director  
**Jeff Brown**

Design Director  
**Charles Lebeda**

Designer  
**Jennifer Rittmann**

Director of Sales,  
Managed Markets Group  
**Phil Talamo**

National Accounts Managers  
**Gene Conselyea**  
**Andrew Colon**  
**Phil Lindner**

## Corporate

Chairman/Chief Executive Officer/  
President  
**Mike Hennessy**

Chief Financial Officer  
**Neil Glasser, CPA/CFE**

President, Managed Markets  
**Brian Haug**

Executive Vice President,  
Executive Director of Education  
**Judy V. Lum, MPA**

Executive Assistant  
**Teresa M. Fallon-Yandoli**

Copyright © 2012 by Managed Care  
& Healthcare Communications, LLC

November 2012 – Vol. 18, No. 11, Sup.

## New Approaches to Measuring Value in Oncology Therapy

### Table of Contents

#### Participating Faculty **S246**

#### Reports

#### ■ Dynamic Cost-Effectiveness of Oncology Drugs **S249**

**Yang Lu, PhD; John R. Penrod, PhD; Neeraj Sood, PhD; Saarah Woodby, BA; and Tomas Philipson, PhD**

#### ■ Value of Survival Gains in Chronic Myeloid Leukemia **S257**

**Wesley Yin, PhD; John R. Penrod, PhD; J. Ross Maclean, MD; Darius N. Lakdawalla, PhD; and Tomas Philipson, PhD**

#### ■ The Option Value of Innovative Treatments in the Context of Chronic Myeloid Leukemia **S265**

**Yuri Sanchez, PhD; John R. Penrod, PhD; Xiaoli Lily Qiu, PhD; John Romley, PhD; Julia Thornton Snider, PhD; and Tomas Philipson, PhD**

#### ■ Coverage and Use of Cancer Therapies in the Treatment of Chronic Myeloid Leukemia **S272**

**Theodore Darkow, PharmD; J. Ross Maclean, MD; Geoffrey F. Joyce, PhD; Dana Goldman, PhD; and Darius N. Lakdawalla, PhD**



# MH

A Supplement to *The American Journal of Managed Care*

www.ajmc.com

PROJ A386

---

# *New Approaches to Measuring Value in Oncology Therapy*

This supplement was supported by **Bristol-Myers Squibb**.

• • •

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

## New Approaches to Measuring Value in Oncology Therapy

This supplement to *The American Journal of Managed Care* reports the results of 4 studies analyzing novel aspects of the value generated by oncology agents. These 4 studies lay out new approaches to incorporating dynamic and patient-centered considerations into value and cost-effectiveness calculations. These findings may help managed care organizations better understand and quantify the value oncology therapies produce for patients with cancer.

### ■ Faculty

#### **Theodore Darkow, PharmD**

Director  
Health Services  
US Medical  
Bristol-Myers Squibb  
Plainsboro, New Jersey

#### **Dana Goldman, PhD**

Director  
Leonard D. Schaeffer Center for Health Policy and Economics  
Professor  
Norman Topping Chair in Medicine and Public Policy  
USC Sol Price School of Public Policy  
School of Pharmacy  
University of Southern California  
Los Angeles, California

#### **Geoffrey F. Joyce, PhD**

Director of Health Policy  
Leonard D. Schaeffer Center for Health Policy and Economics  
Associate Professor  
Pharmaceutical Economics and Policy  
School of Pharmacy  
University of Southern California  
Los Angeles, California

#### **Darius N. Lakdawalla, PhD**

Director of Research  
Leonard D. Schaeffer Center for Health Policy and Economics  
Quintiles Professor of Pharmaceutical and Regulatory Innovation  
School of Pharmacy  
Sol Price School of Public Policy  
University of Southern California  
Los Angeles, California

#### **Yang Lu, PhD**

Assistant Professor of Research  
Leonard D. Schaeffer Center for Health Policy and Economics  
School of Medicine  
University of Southern California  
Los Angeles, California

#### **J. Ross Maclean, MD**

Vice President  
Cardiovascular and Metabolics  
Bristol-Myers Squibb  
Plainsboro, New Jersey

#### **John R. Penrod, PhD**

Director  
Health Services, Oncology  
US Medical  
Bristol-Myers Squibb  
Plainsboro, New Jersey

#### **Tomas Philipson, PhD**

Daniel Levin Professor of Public Policy Studies  
Harris Graduate School of Public Policy  
University of Chicago  
Chicago, Illinois

**Xiaoli Lily Qiu, PhD**

Analytic Consultant  
Precision Health Economics  
Los Angeles, California

**John Romley, PhD**

Research Assistant Professor  
Leonard D. Schaeffer Center for Health Policy and Economics  
Sol Price School of Public Policy  
University of Southern California  
Los Angeles, California

**Yuri Sanchez, PhD**

Research Economist  
Precision Health Economics  
Los Angeles, California

**Julia Thornton Snider, PhD**

Research Economist  
Precision Health Economics  
Los Angeles, California

**Neeraj Sood, PhD**

Director of International Programs  
Leonard D. Schaeffer Center for Health Policy and Economics  
Associate Professor  
Pharmaceutical Economics and Policy  
School of Pharmacy  
University of Southern California  
Los Angeles, California

**Saarah Woodby, BA**

Intern/Consultant  
Bristol-Myers Squibb  
Plainsboro, New Jersey

**Wesley Yin, PhD**

Assistant Professor  
Department of Economics  
Boston University  
Boston, Massachusetts

■ **Faculty Disclosures**

These faculty report relationships with the following organizations:

**Theodore Darkow, PharmD**

*Employee/stock ownership:*  
Bristol-Myers Squibb

**Dana Goldman, PhD**

*Consultant:*  
Bristol-Myers Squibb  
*Partnership:*  
Precision Health Economics

**Geoffrey F. Joyce, PhD**

*Consultant:*  
Precision Health Economics

■ PARTICIPATING FACULTY ■

**Darius N. Lakdawalla, PhD**

*Consultant:*

Bristol-Myers Squibb

*Partnership:*

Precision Health Economics

**J. Ross Maclean, MD**

*Employee/stock ownership:*

Bristol-Myers Squibb

**John R. Penrod, PhD**

*Employee/stock ownership:*

Bristol-Myers Squibb

**Tomas Philipson, PhD**

*Consultant:*

Bristol-Myers Squibb

*Partnership:*

Precision Health Economics

**Xiaoli Lily Qiu, PhD**

*Consultant:*

Precision Health Economics

**John Romley, PhD**

*Consultant:*

Precision Health Economics

**Yuri Sanchez, PhD**

*Employee:*

Precision Health Economics

**Julia Thornton Snider, PhD**

*Employee:*

Precision Health Economics

**Neeraj Sood, PhD**

*Consultant:*

Precision Health Economics

**Sarah Woodby, BA**

*Consultant:*

Bristol-Myers Squibb

**Wesley Yin, PhD**

*Consultant:*

Precision Health Economics

**Yang Lu, PhD**, reports no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this supplement.

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Plainsboro, New Jersey.